• This record comes from PubMed

Selective serotonin reuptake inhibitors use and the risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with one million participants

. 2022 Jul ; 78 (7) : 1199-1200. [epub] 20220311

Language English Country Germany Media print-electronic

Document type Letter, Comment

Links

PubMed 35274148
DOI 10.1007/s00228-022-03309-y
PII: 10.1007/s00228-022-03309-y
Knihovny.cz E-resources

Comment On

PubMed

See more in PubMed

Chen VC, Lin CF, Hsieh YH, Liang HY, Huang KY, Chiu WC, Lee Y, McIntyre RS, Chan HL (2017) Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget 8(18):30464–30470. https://doi.org/10.18632/oncotarget.12826 PubMed DOI

Bhagavathula AS, Woolf B, Rahmani J, Vidyasagar K, Tesfaye W (2022) Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma: a systematic review and dose–response analysis of cohort studies with one million participants. Eur J Clin Pharmacol 1–9

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16(10):589–604. https://doi.org/10.1038/s41575-019-0186-y PubMed DOI PMC

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...